TICKERNERD
Menu
TRVITRVIHealthcare · Biotechnology

TRVI Stock Forecast: Trevi Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$12
−1.87% on the day

The 11 Wall Street analysts covering Trevi Therapeutics, Inc. hold a median 12-month price target of $25 — +107.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 14 Oct 2026 — in the lower half.

Market cap
$1.7B
Ticker Nerd rank
48 / 100
Median analyst target
$25
Analysts covering
11
Revenue$0.0
Operating income−$20.5M
Net income−$17.8M
Free cash flow−$17.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.2%
1M
−24.1%
YTD
−3.7%
1Y
+18.4%
From 52W high
−38.2%
From 52W low
+20.7%
$10
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TRVI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Trevi Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
79
Momentum
74
Volatility
73
Quality
68
Growth
44
Issuance
37
Size
37
Revisions
35
Accruals
33

Value (79): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (33): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TRVI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TRVI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40Jan 26Apr 26Jul 26Oct 26TRVIHigh $40Median $25Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $23Median $25High $40

The green dot is the last close — the median target sits +107.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 Aug 2026Jones TradingMaintainsBuy$24 → $28
7 Aug 2026Cantor FitzgeraldMaintainsOverweight$25 → $30
7 Aug 2026OppenheimerMaintainsOutperform$24 → $25
21 July 2026BMO CapitalInitiatesOutperform$36
21 July 2026BMO CapitalInitiatesOutperform—
20 July 2026B. Riley SecuritiesMaintainsBuy—
20 July 2026B. Riley SecuritiesMaintainsBuy$21 → $31
20 July 2026HC Wainwright & Co.MaintainsBuy—
20 July 2026HC Wainwright & Co.MaintainsBuy$21 → $24
20 May 2026NeedhamReiteratesBuy—
20 May 2026NeedhamReiteratesBuy$23
6 May 2026HC Wainwright & Co.ReiteratesBuy—
6 May 2026NeedhamMaintainsBuy—
17 Apr 2026D. Boral CapitalMaintainsBuy—
19 Mar 2026Jones TradingMaintainsBuy—
18 Mar 2026D. Boral CapitalMaintainsBuy—
18 Mar 2026Morgan StanleyMaintainsOverweight—
18 Mar 2026NeedhamMaintainsBuy—
9 Mar 2026D. Boral CapitalMaintainsBuy—
9 Mar 2026HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TRVI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TRVI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Trevi Therapeutics, Inc. returned +18.4% against +17.5% for the S&P 500, dividends included.

TRVI vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Jan 26Apr 26Jul 26Oct 26TRVIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TRVI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
7
Fundamentals

Trevi Therapeutics, Inc. (TRVI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−37.7×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
5.3×

Cheaper than 18% of US stocks

EV / EBITDA
−24.1×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−19.7%

Higher than 31% of US stocks

Return on assets
−13.8%

Higher than 23% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Trevi Therapeutics, Inc. (TRVI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Trevi Therapeutics, Inc. has a market value of $1.7B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$51.1M.

  • Diluted earnings per share, trailing twelve months: $−0.34.

  • Free cash flow in the twelve months to 30 June 2026: −$52.9M.

  • Shares outstanding: 142.0M.

  • Trailing P/E: −37.7×; forward P/E: −20.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Trevi Therapeutics, Inc. employs 34 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

TRVI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TRVITrevi Therapeutics, Inc.$1.7B
48
XNCRXencor, Inc.$1.7B
84
BRVEBraveheart Bio, Inc.$1.7B
0
MRVIMaravai Lifesciences Holdings, Inc.$1.7B
86
PVLAPalvella Therapeutics, Inc.$1.8B
30
VIRVir Biotechnology, Inc.$1.8B
92
SRPTSarepta Therapeutics, Inc.$1.8B
73

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Trevi Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TRVI news & analysis

Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting

GlobeNewsWire · 13 Oct 2026positive

Trevi Therapeutics announced that Professor Philip Molyneaux will give an oral presentation at the CHEST 2026 Annual Meeting on patient-reported outcomes from the Phase 2b CORAL trial of nalbuphine ER for chronic cough in people with idiopathic pulmonary fibrosis.

Why it matters — The presentation will share patient-reported outcome findings from a clinical trial of Trevi’s nalbuphine ER in chronic cough associated with IPF.

Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Trevi Therapeutics, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation is available. No details of the presentation's content are provided in the item.

Why it matters — A TRVI watcher would care because the transcript offers an opportunity to hear company management's commentary at a major industry investor conference.

Trevi Therapeutics to Participate in Upcoming September Conferences

GlobeNewsWire · 3 Sept 2026neutral

Trevi Therapeutics, a clinical-stage biopharmaceutical company developing Haduvio for chronic cough, announced that its senior management will participate in several conferences in September. The announcement confirms the company's scheduled investor and industry engagement activities for the month.

Why it matters — TRVI watchers would care because the September conference appearances give management opportunities to present the company's Haduvio program and developments to investors and the broader healthcare community.

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

GlobeNewsWire · 26 Aug 2026positive

Trevi Therapeutics announced upcoming presentations at the European Respiratory Society (ERS) Congress 2026. Professor Marlies Wijsenbeek will deliver an oral presentation on quality-of-life outcomes measured by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for patients with IPF-related chronic cough.

Why it matters — This presentation highlights progress and visibility for Trevi's nalbuphine ER program in treating IPF-related chronic cough.

Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform

Seeking Alpha · 20 Aug 2026positive

The article highlights Trevi Therapeutics' specialty-pharma strategy centered on Haduvio, whose dual mechanism targets IPF-related chronic cough with planned expansion into non-IPF ILD and refractory chronic cough. It notes positive Phase II data in both indications, ongoing pivotal trials, and robust liquidity supporting the company's transition toward a specialty platform.

Why it matters — A TRVI watcher would care because the article frames Haduvio's dual mechanism, promising trial data, and focused pulmonology strategy as groundwork for building a broader chronic-cough platform beyond a single indication.

FAQ

Frequently asked questions about TRVI stock

What is the TRVI stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Trevi Therapeutics, Inc. have a median 12-month price target of $25, with estimates ranging from $23 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TRVI stock a buy right now?

Of the 11 analysts covering Trevi Therapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Trevi Therapeutics, Inc. 48 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TRVI?

As at 14 Oct 2026, Trevi Therapeutics, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (79 of 100).

Will TRVI stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +107.3% from the last close, and Ticker Nerd's factor model ranks Trevi Therapeutics, Inc. 48 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TRVI stock forecast for 2030?

No analyst covering Trevi Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TRVI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $40 over the next 12 months.

How has TRVI stock performed over the past year?

Trevi Therapeutics, Inc. returned +18.4% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Trevi Therapeutics, Inc. do?

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing investigational therapies for serious neurologically mediated conditions.

What is the latest news on TRVI?

The most recent item we track (GlobeNewsWire, 13 Oct 2026): "Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting". Trevi Therapeutics announced that Professor Philip Molyneaux will give an oral presentation at the CHEST 2026 Annual Meeting on patient-reported outcomes from the Phase 2b CORAL trial of nalbuphine ER for chronic cough in people with idiopathic pulmonary fibrosis.

Company

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing investigational therapies for serious neurologically mediated conditions. Its lead program, Haduvio, is an oral extended-release formulation of nalbuphine designed to address chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. The company also works on therapies for chronic pruritus and other conditions where opioid receptor modulation may help control symptoms. Trevi Therapeutics serves the specialty respiratory and neurology-adjacent treatment markets, with a business model centered on advancing targeted drug candidates through clinical development and toward potential commercialization. Based in New Haven, Connecticut, Trevi Therapeutics, Inc. focuses on unmet needs in chronic symptom management and operates within the broader biopharmaceutical innovation sector.

CEO Ms. Jennifer L. Good · 34 employees · United States · https://www.trevitherapeutics.com